Hemodynamic Aberrancies in Left Ventricular Assist Device –Associated Heart Failure Syndromes

The advent of the fully magnetically levitated HeartMate 3 left ventricular assist device (LVAD) has enabled a marked reduction in hemocompatibility-related adverse events, with a near-elimination of pump thrombosis, and a marked decrease in stroke in LVAD recipients.1,2 As a result, a survival benchmark for LVAD therapy has been established —prolongation of the median survival of more than 5 years in patients with advanced heart failure with otherwise severely limited 1-year survival.3
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Tags: JCF Ignite! Source Type: research